GoodRx Holdings, Inc.
GoodRx Holdings, Inc. (GDRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gdrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for GoodRx Holdings, Inc. (GDRX) measures how much investors pay for each dollar of the company's trailing earnings. GDRX's current PE ratio of 44.23x is calculated by dividing its stock price of $2.67 by its TTM earnings per share of $0.06. −92.7% discount vs 5Y avg 605.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 5 fiscal years · Front-end computedMinQ1 · 25%272.2x
MedianQ3 · 75%2200.8x
Max
At 44.23x, GDRX's current P/E is lower than in 20% of its annual fiscal year readings over the past 5 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Healthcare Information Services · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
GoodRx Holdings, Inc.You GDRX | $927M | 44.23x | +124.4% | $0.06 |
 AdaptHealth Corp. AHCO | $1.3B | N/A | — | -$0.52 |
 Amphastar Pharmaceuticals, Inc. AMPH | $858M | 12.76x | -35.3% | $2.10 |
 Collegium Pharmaceutical, Inc. COLL | $1.1B | 23.35x | +18.5% | $1.98 |
 Claritev Corporation CTEV | $454M | N/A | — | -$17.30 |
 HealthStream, Inc. HSTM | $749M | 37.76x | +91.6% | $0.61 |
 Innoviva, Inc. INVA | $1.6B | 4.97x | -74.8% | $4.02 |
Industry Average 4 peers with valid PE | — | 19.71x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 31.72x | $0.09 | -71.0% | |
2024-12-31 FY2024 | 109.44x | $0.04 | — | |
2023-12-31 FY2023 | — | $-0.02 | — | |
2022-12-31 FY2022 | — | $-0.08 | — | |
2021-12-31 FY2021 | — | $-0.06 | — | |
2020-12-31 FY2020 | — | $-1.07 | — | |
2019-12-31 FY2019 | 272.25x | $0.19 | -33.7% | |
2018-12-31 FY2018 | 410.60x | $0.12 | -81.3% | |
2017-12-31 FY2017 | 2200.83x | $0.02 | — | |
2016-12-31 FY2016 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for GoodRx Holdings, Inc. (GDRX) measures how much investors pay for each dollar of the company's trailing earnings. GDRX's current PE ratio of 44.23x is calculated by dividing its stock price of $2.67 by its TTM earnings per share of $0.06.
Frequently asked questions
GDRX pe ratio · 6 questionsGDRX's current PE ratio is 44.23x as of 2026-06-08, based on a stock price of $2.67 and TTM EPS of $0.06. Data sourced from Financial Modeling Prep via GDRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GoodRx Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08